Last updated on March 2020

A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: NIDDM | Diabetes Mellitus Type 2 | Type 2 | Diabetes Mellitus
  • Age: Between 20 - 70 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Have T2DM for at least 6 months before screening and are without advanced known possible complications of diabetes mellitus
  • Have a glycated hemoglobin (HbA1c) value at lead-in and screening of 7.0% and 10.5% and treated with diet and exercise alone or a stable dose of metformin for at least 3 months prior to screening
  • Have had a stable body weight for the 3 months prior to randomization (<5% body weight change)
  • Have a body mass index of 23 to 50 kilograms per square meter (kg/m), inclusive
  • Male participants agree to use an effective method of contraception for the duration of the study plus 90 days, which corresponds to 4 months after the last investigational product dose
  • Women not of childbearing potential may participate and include those who are: infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as mullerian agenesis; or those who are postmenopausal

Exclusion Criteria:

  • Have type 1 diabetes mellitus or latent autoimmune diabetes in adults
  • Have uncontrolled diabetes, defined as an episode of ketoacidosis or hyperosmolar state requiring hospitalization in the 6 months prior to screening
  • Have a known clinically significant gastric emptying abnormality
  • Have had an episode of severe hypoglycemia
  • Have a history of acute or chronic pancreatitis or fasting serum triglyceride level of >500 milligrams per deciliter (mg/dL) at screening and/or Day2. If participant is on lipid-lowering therapies, doses must be stable for 30 days prior to screening
  • Have known liver disease, obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or have elevations in aminotransferases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) greater than 3X upper limit of normal (ULN) at screening and/or Day -2

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.